Reference: JAMA Intern Med. 2026 Apr 1;186(4):456-468
Practice Point: Once-daily umeclidinium-vilanterol may be associated with fewer COPD exacerbations than other LAMA-LABAs, and it’s better for the environment as well.
EBM Pearl: The safety, cost, tolerability, and ease of use of a drug all contribute to sometimes-meaningful differences between efficacy and effectiveness.
Guidelines recommend long-acting muscarinic antagonist–long-acting beta-2 agonist (LAMA-LABA) therapy for chronic obstructive pulmonary disease (COPD). Unfortunately, "follow guideline recommendations" is not a selectable medication in the order field of most electronic health records, leaving clinicians with little guidance on which medication is best for their patients. Fixed-dose combinations come in 3 forms: dry powder, soft mist, and metered-dose inhalers. These generally have different molecules, dosing frequencies, and delivery mechanisms. Until now, head-to-head data on effectiveness have been sparse, underpowered, or limited by geography. A large study, published in JAMA Internal Medicine, makes a welcome attempt to fill that gap.
Researchers used a claims database of over 95 million commercially insured and Medicare Advantage patients to construct 3 propensity score-matched cohorts comparing the 3 most-prescribed LAMA-LABAs in the United States: once-daily dry powder umeclidinium-vilanterol (Anoro Ellipta), twice-daily metered-dose inhaler glycopyrrolate-formoterol (Bevespi Aerosphere), and once-daily soft mist inhaler tiotropium-olodaterol (Stiolto Respimat).
The primary outcome was time to first moderate or severe COPD exacerbation, with safety outcomes including major adverse cardiac events (MACE), urinary tract infections (UTI), and pneumonia hospitalizations. The headline numbers may not be dramatic, but they are clinically meaningful. Umeclidinium-vilanterol was associated with a 14% lower hazard of moderate or severe exacerbation compared to glycopyrrolate-formoterol (hazard ratio [HR] 0.86, 95% CI 0.81-0.91, NNT 17) and a 3% lower hazard compared to tiotropium-olodaterol (HR 0.97, 95% CI 0.94-0.99, NNT 100). Tiotropium-olodaterol was associated with a 6% lower hazard compared to glycopyrrolate-formoterol (HR 0.94, 95% CI 0.89-1).
Regarding medication safety, no differences in MACE, UTI, or pneumonia hospitalizations were seen across all comparators. The findings held up across a comprehensive array of sensitivity analyses, including varying grace periods, outcome definitions, follow-up windows, and statistical approaches.
So why would one option perform slightly better? Probably not because it’s pharmacologically superior, but likely because it’s easier to live with. Once-daily dosing tends to win in the real world, and dry powder inhalers generally require fewer steps than metered-dose or soft mist devices. In settings where optimal inhaler technique is not consistently achieved, small differences in real-world use can translate into measurable clinical effects, highlighting the important difference between the efficacy demonstrated during the controlled environment of a trial and real-world effectiveness.
These authors designed this study to compare new users of one active treatment against new users of another, minimizing the immortal time bias and healthy-user effects that often plague observational drug studies. Their propensity score matching was rigorous, and sensitivity analyses yielded near-identical results, which may be a reassuring sign that residual confounding isn’t driving the story.
That said, some caution is warranted. Unmeasured confounders, such as forced expiratory volume in 1 second (FEV1), socioeconomic status, race, and formulary access patterns, could not be fully adjusted for. The NNT of 100 for umeclidinium-vilanterol vs. tiotropium-olodaterol, while statistically significant, is modest and may not shift individual clinical decision-making. And like all claims-based studies, the data capture prescription fills, not puffs inhaled.
Still, for most patients newly initiating LAMA-LABA therapy, this study offers compelling real-world evidence that umeclidinium-vilanterol (Anoro Ellipta) appears to be the best-performing option. As an added bonus, it also emits roughly one-twentieth as much greenhouse gas as the metered-dose alternative. So, if you want to feel a little like an environmental caped crusader, consider this a good alternative in managing COPD. Your patients’ lungs, and arguably the atmosphere, will thank you.
For more information, see the topic Bronchodilators for COPD in DynaMed.
DynaMed EBM Focus Editorial Team
This EBM Focus was written by Rich Lamkin, MPH, MPAS, PA-C, Senior Clinical Writer at DynaMed. Edited by Katharine DeGeorge, MD, MS, Executive Editor at DynaMed and Professor of Family Medicine at the University of Virginia; Alan Ehrlich, MD, FAAFP, Executive Editor at DynaMed and Associate Professor in Family Medicine at the University of Massachusetts Medical School; McKenzie Ferguson, PharmD, BCPS, Senior Clinical Writer at DynaMed; Claire Symanski, PhD, Medical Editor and Team Lead for ENT at DynaMed; Michael Butler, PhD, Medical Writer at DynaMed; Matthew Lavoie, BA, Senior Medical Copyeditor at DynaMed; Hannah Ekeh, MA, Senior Associate Editor II at DynaMed; and Jennifer Wallace, BA, Senior Associate Editor at DynaMed.